AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%
Adding a newer checkpoint inhibitor to anti-PD-1 therapy did not improve lung cancer survival, providing important evidence that guides better clinical trial design going forward.
This Phase 3 RCT demonstrates that adding an anti-TIGIT antibody (ociperlimab) to anti-PD-1 (tislelizumab) does not improve overall survival versus pembrolizumab monotherapy in first-line PD-L1 ≥50% NSCLC, with comparable median OS across all arms (27.7–31.9 months). The negative result contributes critical evidence to the TIGIT inhibitor field, which has seen multiple Phase 3 failures, and supports the emerging consensus that TIGIT co-inhibition may not improve outcomes in PD-L1-high lung cancer.
What the study was
- Study design
- phase_3_randomized_clinical_trial
- Category
- novel_therapeutics_immunotherapy
- Maturity
- Validated
- Journal
- Journal of Thoracic Oncology
Why it surfaced
Important negative Phase 3 result in a highly competitive NSCLC immunotherapy space; adds to the pattern of TIGIT inhibitor Phase 3 failures and has immediate implications for pipeline decisions. Score 7 (N=2, D=2, P=2, E=1) reflects Phase 3 design (D=2) and active treatment landscape unmet need (P=2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.